# OnCo record futibatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/futibatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "futibatinib" ;
  schema:name "Futibatinib"@en ;
  schema:description "Futibatinib is a covalent FGFR inhibitor for FGFR2-fusion bile duct cancer, with the highest response rate of the first-generation drugs."@en ;
  schema:url <https://onco.cc/drugs/futibatinib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Futibatinib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q76791462> ;
  schema:citation <https://www.nejm.org/doi/full/10.1056/NEJMoa2206834>, <https://www.nice.org.uk/guidance/ta1005> ;
  onco:status "approved" ;
  onco:modality "Small-molecule irreversible kinase inhibitor (FGFR1-4)" ;
  schema:alternateName "Lytgobi" ;
  onco:approval "US 2022: Previously treated FGFR2-fusion/rearranged intrahepatic cholangiocarcinoma (accelerated)", "EU 2023: Same", "UK 2024: Locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement after at least one systemic treatment; NICE TA1005 recommended 11 September 2024 as an alternative to pemigatinib" ;
  onco:acceleratedApproval "US 2022-09-30: Adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements" ;
  onco:related <https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/> ;
  onco:cancers <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/fgfr2/> ;
  onco:companies <https://onco.cc/companies/taiho/> ;
  onco:terms <https://onco.cc/terms/fgfr2-fusion/> ;
  onco:trials <https://onco.cc/trials/foenix-cca2/>, <https://onco.cc/trials/nct06506955/>, <https://onco.cc/trials/nct07710885/>, <https://onco.cc/trials/nct05945823/> .